A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants

NCT05445232 · Completed

Last updated 2026-05-28

This clinical trial is testing how a new drug, LY3437943, affects the levels of midazolam in the bloodstream of obese participants.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) basic-science study

Participants 32 people

Who can join Ages 18–70 · all sexes

Timeline Started 2022-07 · est. completion 2023-02

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT05445232 ↗

Description as written by the study sponsor.

The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of midazolam, warfarin and caffeine in the blood stream when administered orally as a drug cocktail in obese participants. This study will last up to approximately 25 weeks for each participant.

Treatments tested

LY3437943 Drug

Administered SC.
Midazolam Drug

Administered orally.
Warfarin Drug

Administered orally.
Caffeine Drug

Administered orally.

Main thing measured	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Midazolam
Sponsor	Eli Lilly and Company
Conditions studied	Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05445232 ↗